tetano
Editor, Senior Moderator
Front Immunol
. 2022 Aug 4;13:902260.
doi: 10.3389/fimmu.2022.902260. eCollection 2022.
Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
Blake M Hauser[SUP] 1 [/SUP], Maya Sangesland[SUP] 1 [/SUP], Evan C Lam[SUP] 1 [/SUP], Jared Feldman[SUP] 1 [/SUP], Alejandro B Balazs[SUP] 1 [/SUP], Daniel Lingwood[SUP] 1 [/SUP], Aaron G Schmidt[SUP] 1 2 [/SUP]
Affiliations
Abstract
Since the emergence of SARS-CoV-2 (SARS-2), multiple vaccine candidates were developed and studied both preclinically and clinically. Nearly all are based on the SARS-2 spike glycoprotein or its receptor binding domain (RBD). Studies of these vaccine candidates have largely been in a SARS-2 naïve context. However, pre-existing immunity to SARS-2 acquired through infection or vaccination continues to increase. Evaluating future vaccine candidates in context of this pre-existing immunity is necessary to understand how immune responses are subsequently influenced. Here, we evaluated the serum and IgG[SUP]+[/SUP] B cell responses to the SARS-2 RBD in context of pre-existing immunity elicited by the full SARS-2 spike, and we compared this to boosting with the full SARS-2 spike. Boosting with the SARS-2 RBD resulted in increased reactivity to RBD epitopes, but both immunization regimens resulted in similarly broad neutralization across diverse sarbecoviruses. These findings may inform comparison among SARS-2 RBD-based vaccine candidates to currently approved spike-based candidates.
Keywords: SARS-CoV-2; coronavirus; immune imprinting; receptor binding domain (RBD); spike (S).
. 2022 Aug 4;13:902260.
doi: 10.3389/fimmu.2022.902260. eCollection 2022.
Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
Blake M Hauser[SUP] 1 [/SUP], Maya Sangesland[SUP] 1 [/SUP], Evan C Lam[SUP] 1 [/SUP], Jared Feldman[SUP] 1 [/SUP], Alejandro B Balazs[SUP] 1 [/SUP], Daniel Lingwood[SUP] 1 [/SUP], Aaron G Schmidt[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35990628
- PMCID: PMC9386501
- DOI: 10.3389/fimmu.2022.902260
Abstract
Since the emergence of SARS-CoV-2 (SARS-2), multiple vaccine candidates were developed and studied both preclinically and clinically. Nearly all are based on the SARS-2 spike glycoprotein or its receptor binding domain (RBD). Studies of these vaccine candidates have largely been in a SARS-2 naïve context. However, pre-existing immunity to SARS-2 acquired through infection or vaccination continues to increase. Evaluating future vaccine candidates in context of this pre-existing immunity is necessary to understand how immune responses are subsequently influenced. Here, we evaluated the serum and IgG[SUP]+[/SUP] B cell responses to the SARS-2 RBD in context of pre-existing immunity elicited by the full SARS-2 spike, and we compared this to boosting with the full SARS-2 spike. Boosting with the SARS-2 RBD resulted in increased reactivity to RBD epitopes, but both immunization regimens resulted in similarly broad neutralization across diverse sarbecoviruses. These findings may inform comparison among SARS-2 RBD-based vaccine candidates to currently approved spike-based candidates.
Keywords: SARS-CoV-2; coronavirus; immune imprinting; receptor binding domain (RBD); spike (S).